Why the EMvision (ASX: EMV) share price closed 13% higher today

The EMvision (ASX: EMV) share price finished 13% higher today after the company announced grant success. Here's the rundown.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The EMvision Medical Devices Ltd (ASX: EMV) share price closed 13.2% higher today after the company made a funding announcement.

The EMvision share price finished off the trading session at $2.74 this afternoon.

Here's a wrap of where the funding will come from for the medical imaging technology provider, and why it may have moved the share price.

Rising healthcare ASX share price represented by doctor giving thumbs up

Image source: Getty Images

Australian Stroke Alliance wins bid

In today's release, EMvision advised that its commercial collaboration partner, the Australian Stroke Alliance (ASA), submitted a successful bid to the Stage 2 Medical Research Future Fund (MRFF) for a 5-year program to transform pre-hospital stroke care. 

The MRFF stage 2 program was awarded $100 million from the federal government, with 40 million allocated to ASA. 

Of the $40 million, ASA has advised EMVision that it will receive "$8 million of this non-dilutive cash funding in staged payments weighted to the earlier years of the program". 

This poses the opportunity for EMvision to commercialise its medical imaging technology and work toward further developments.

Executive commentary on funding

Commenting on the ASA collaboration, EMvision CEO Dr Ron Weinberger said:

The ASA brings together an end-to-end medical program to save and improve the lives of patients of one of the most debilitating medical emergencies in the world. No such consortium exists internationally, and the ASA will become a template for not only managing stroke, but other medical emergencies.

The ASA leadership has worked tirelessly to put Australia centre stage in this global battle to save healthy lives and is to be congratulated. We are grateful to the Australian government for recognising this vision and awarding one of the largest medical research grants in Australian history.

ASA co-chief investigator and neurologist, Professor Geoffrey Donnan, added:

We are excited to be commencing this ground-breaking research program. Lightweight portable and affordable brain imaging is the next frontier in stroke care…"

EMvision share price snapshot

Despite falling 22.4% year-to-date, the EMvision share price has gained 20.1% over the previous 6-month period.

The company's market capitalisation is approximately $171.2 million, and 70.8 million shares are outstanding.

Gretchen Kennedy has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of EMvision Medical Devices Limited. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Share Market News

Share Market News

Testing again

Read more »

Share Market News

Aaron Test 2

Read more »

Share Market News

Aaron Test

Read more »

Share Market News

JP Test

Read more »

Share Market News

JP Test

Read more »

Portrait of Discovery Fund portfolio managers Mark Devcich and Chris Bainbridge
Share Market News

Test

Portfolio managers Mark Devcich (left) and Chris Bainbridge. Image source: Discovery Fund test test

Read more »

a man in a hoodie grins slyly as he sits with his hands poised on a keyboard. He is superimposed with a graphic image of a computer screen asking for a password, suggesting he is a hacker.
Share Market News

Another ASX 200 company has been hit with a cyber incident. Here's what we know

Hackers have breached the systems of this ASX 200 company.

Read more »

a woman
Broker Notes

5 ASX 200 shares that inflation can't touch: expert

Regardless of whether you're a bull or a bear, cost pressures are a factor when buying stocks at the moment.

Read more »